Using CAST-test to investigate human specific hypersensitivity to the anthrax pathogen

We present the results of applying functional cytometric test of antigen-stimulated activation basophils to assess specific immunological reactivity in the people with anthrax, and immunized with anthrax vaccine. As a criterion for antigen-specific basophil activation, we measured expression of the CD63 membrane receptor, which reflects the process of anaphylactic basophil degranulation. To determine spontaneous and antigen-induced activation of basophils (CCR3+CD63+), a FlowCAST reagent kit (Buhlmann laboratories AG, Switzerland) was used. Anthraxin, an experimental anthrax allergen (a hydrolysate the Bacillus anthracis STI-1 strain), manufactured by the Stavropol Anti-Plague Institute, was used as a specific antigen. As based on clinical and experimental data, a threshold value of > 10% of anthraxin-activated (CCR3+CD63+) basophils was accepted for the in vitro immunodiagnostic CAST test, as a laboratory criterion for the subjects exhibiting specific immune response, i.e., IgE-mediated sensitization. It was shown that, in anthrax patients within one week after onset of the disease (3-7 days), a positive CAST result was obtained in 92.3% cases; the levels of specific basophil activation with anthraxin averaged 37.9% (12.01 ÷ 78.9%). Immunological examination of individuals three weeks (21 days) after vaccination against anthrax revealed CAST-positivity in all the vaccinated persons. Intensity of anthraxin-induced basophil activation the vaccinated subjects was ranged from 10.87 to 30.03%, averaging 17.86%. The overall values of spontaneous and specific activation ranged within 12.39 ÷ 41.46%. The study opens prospectives for implementation of basophil antigenic activation test in the Flow CAST format in diagnostics of anthrax and to identify specific immune rearrangements after vaccination in humans, as an index of actual vaccination rates. Usage of CAST test with anthraxin makes it possible to identify anthrax patients at the early stages (2-4 days after onset of the disease) including, among patients with an increased CCR3+CD63+ background values, evaluation of immunological efficiency in the cohorts at risk for vaccination. At the same time, it was found that a significant decrease in diagnostic sensitivity of CAST test could be observed in the patients immune to anthrax pathogen who received intensive antibacterial and pathogenetic therapy at the early stages of infection, including glucocorticosteroids (anti-inflammatory drugs) and desensitizing agents that inhibit the degree of hypersensitivity development and its expression.

1. Safety of work with microorganisms of I-II pathogenicity (danger) groups: sanitary and epidemiological rules]. Moscow: Federal Center for Hygiene and Epidemiology of Rospotrebnadzor, 2014. 195 p.

2. GOST R 53022.3-2008 Clinical laboratory technologies. Requirements for quality of clinical laboratory tests. Part

3. GOST R 53079.4-2008 Clinical laboratory technologies. Quality assurance of clinical laboratory tests. Part 4. Rules for conducting of preanalytical stage.

4. Demina Yu.V., Riazanova A.G., Aksenova L.Yu., Kuznetsova I.V., Kotenev E.S., Golovinskaya T.M., Buravtseva N.P., Eremenko E.I., Ponomarenko D.G., Rakitina E.L., Kostyuchenko M.V., Tsygankova O.I., Koteneva E.A., Dyatlov I.A., Timofeev V.S., Bakhteeva I.V., Kartavaya S.A., Nechepurenko L.A., Kharkiv V.V., Kosareva L.E., Erdni-Goryaeva G.V., ashenov a.m., Leontieva S. A., tadjidinov V. O. Organization of laboratory research of clinical Material And samples From Environmental Objects during the outbreak of anthrax In the Yamalo-Nenets Autonomous district in 2016 . Problemy osobo opasnykh infektsiy = Problems of Particularly Dangerous Infections, 2017, no. 1, pp. 44-48. (In Russ.)

5. Kulichenko A.N., Rakitina E.L., Ponomarenko D.G., Logvinenko O.V., Ryazanova A.G. Use of the basophil activation test with anthraxin for laboratory (in vitro) diagnostics of anthrax. Problemy osobo opasnykh infektsiy = Problems of Particularly Dangerous Infections, 2012, no. 3 (113), pp. 86-88. (In Russ.)

6. Methodical MUK 4.2.2413-08 “Laboratory diagnostics and detection of anthrax causative agent” Electronic resource. Access mode: http://docs.cntd.ru/document/1200075231.

7. Ponomarenko D.G. a New approach to the comprehensive assessment of immunobiological reactivity of the population subject to vaccination (revaccination) against brucellosis. Epidemiologiya i infektsionnyye bolezni. Aktualnye voprosy = Epidemiology and Infectious Diseases. Current Issues, 2015, no. 3, pp. 28-31. (In Russ.)

8. Ponomarenko D.G., Logvinenko O.V., Sarkisyan N.S., Rakitina E.L., Golub O.G., Kulichenko A.N. a New approach to the allergodiagnostics of brucellosis. Infektsiya i immunitet = Russian Journal of Infection and Immunity, 2013, Vol. 3, no. 1, pp. 89-92. (In Russ.) doi: 10.15789/2220-7619-2013-89-92.

9. Romanova I.V. Goncharov A.E. Basophil activation Test: method technology and its application in clinical practice. Immunopatologiya, allergologiya, infektologiya = Immunopathology, Allergology, Infectology, 2018, no. 1, pp. 26-34. (In Russ.)

10. Urbach V.Yu. Biometric methods. Moscow: Nauka, 1964. 410 p.

11. Federal Law of November 21, 2011 N 323-ФЗ (as amended on April 1, 2020) “On the Basics of Protecting the Health of Citizens in the Russian Federation”.

12. Sheikh M.M. The role of infectious allergy in children with pneumonia. Immunopatologiya, allergologiya, infektologiya = Immunopathology, Allergology, Infectology, 2002, no. 2, pp. 106-110. (In Russ.)

13. Arai T., Sakurai D., Iinuma T., Nakagawa T., Yonekura S., Okamoto Y. Basophils from allergic rhinitis patients show allergen-specific upregulation of thymic stromal lymphopoietin receptor. Ann. Allergy Asthma Immunol., 2018, Vol. 120, no. 2, pp. 155-163.

14. Boumiza R., Debard A.L., Monneret G. The basophil activation test by flow cytometry: recent developments in clinical studies, standardization and emerging perspectives. Clin. Mol. Allergy, 2005, Vol. 3, 9. doi:10.1186/1476-7961-3-9.

15. Chirumbolo S., Vella A., Ortolani R., De Gironcoli, M., Solero, P., Tridente, G., Bellavite, P. Differential response of human basophil activation markers: a multi-parameter flow cytometry approach. Clin. Mol. Allergy, 2008, no. 6, pp. 12-16.

16. Ducrest S., Meier F., Tschopp C., Pavlovic R., Dahinden C.A. Flowcytometric analysis of basophil counts in human blood and inaccuracy of hematology analyzers. Allergy, 2005, Vol. 60, no. 11, pp. 1446-1450.

17. Eberlein B., Hann R., Eyerich S., Pennino D., Ring J., Schmidt-Weber C.B., Buters J. Optimizing of the basophil activation test: comparison of different basophil identification markers. Cytometry B Clin. Cytom., 2015, Vol. 88, no. 3, pp. 183-189.

18. Hausmann O.V., Gentinetta T., Fux M., Ducrest S., Pichler W.J., Dahinden C.A. Robust expression of CCR3 as a single basophil selection marker in flow cytometry. Allergy, 2011, Vol. 66, no. 1, pp. 85-91.

19. Hemmings O., Kwok M., McKendry R., Santos A.F. Basophil activation test: old and new applications in allergy. Curr. Allergy Asthma Rep., 2018; Vol. 18, no. 12, 77. doi:10.1007/s11882-018-0831-5.

20. Mikkelsen S., Bibby B.M., Dolberg M.K., Dahl R., Hoffmann H.J. Basophil sensitivity through CD63 or CD203c is a functional measure for specific immunotherapy. Clin. Mol. Allergy, 2010, Vol. 8, no. 1, 2. doi:10.1186/1476-7961-8-2.

21. Mommert S., Kleiner S., Gehring M., Eiz-Vesper B., Stark H., Gutzmer R., Werfel T., Raap U. Human basophil chemotaxis and activation are regulated via the histamine H4 receptor. Allergy, 2016, Vol. 71, no. 9, pp. 1264-1273.

22. Monneret G. Is this time for CRTH2/DP2 in a flow cytometric basophil activation test? Clin. Exp. Allergy, 2008, Vol. 38, no. 7, pp. 1239-1240.

23. Monneret G. CCR3 for basophil activation test: a necessary but insufficient step. Clin. Exp. Allergy, 2010, Vol. 40, no. 6, 953. doi: 10.1111/j.1365-2222.2010.03516.x.

24. Prussin C., Metcalfe D.D. IgE, mast cells, basophils, and eosinophils. J. Allergy Clin. Immunol., 2006, Vol. 117, no. 2, pp. 450-456.

25. Sabato V., Boita M., Shubber S., Bridts C.H., Shibuya A., de Clerck L.S., Falcone F.H., Ebo D.G. Mechanism of phosphatidylserine inhibition of IgE/FcepsilonRI-dependent anaphylactic human basophil degranulation via CD300a. J. Allergy Clin. Immunol., 2014, Vol. 134, no. 3, pp. 734-737.

26. Santos A.F., Shreffler W.G. Road map for the clinical application of the basophil activation test in food allergy. Clin. Exp. Allergy, 2017, Vol. 47, no. 9, pp. 1115-1124.

27. Witting Christensen S.K., Kortekaas Krohn I., Thuraiaiyah J., Skjold T., Schmid J.M., Hoffmann H.J. Sequential allergen desensitization of basophils is non-specific and may involve p38 MAPK. Allergy, 2014, Vol. 69, no. 10, pp. 1343-1349.

28. Zaidi A.K., Saini S.S., Macglashan D.W. Jr. Regulation of Syk kinase and FcRbeta expression in human basophils during treatment with omalizumab. J. Allergy Clin. Immunol., 2010, Vol. 125, no. 4, pp. 902-908.